Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma

Objectives Yttrium-90 (Y90)-radioembolisation (RE) significantly regresses locally advanced hepatocellular carcinoma and delays disease progression. The current study is designed to deeply interrogate the immunological impact of Y90-RE, which elicits a sustained therapeutic response. Design Time-of-flight mass cytometry and next-generation sequencing (NGS) were used to analyse the immune landscapes of tumour-infiltrating leucocytes (TILs), tumour tissues and peripheral blood mononuclear cells (PBMCs) at different time points before and after Y90-RE. Results TILs isolated after Y90-RE exhibited signs of local immune activation: higher expression of granzyme B (GB) and infiltration of CD8+ T cells, CD56+ NK cells and CD8+ CD56+ NKT cells. NGS confirmed the upregulation of genes involved in innate and adaptive immune activation in Y90-RE-treated tumours. Chemotactic pathways involving CCL5 and CXCL16 correlated with the recruitment of activated GB+CD8+ T cells to the Y90-RE-treated tumours. When comparing PBMCs before and after Y90-RE, we observed an increase in tumour necrosis factor-α on both the CD8+ and CD4+ T cells as well as an increase in percentage of antigen-presenting cells after Y90-RE, implying a systemic immune activation. Interestingly, a high percentage of PD-1+/Tim-3+CD8+ T cells coexpressing the homing receptors CCR5 and CXCR6 denoted Y90-RE responders. A prediction model was also built to identify sustained responders to Y90-RE based on the immune profiles from pretreatment PBMCs. Conclusion High-dimensional analysis of tumour and systemic immune landscapes identified local and systemic immune activation that corresponded to the sustained response to Y90-RE. Potential biomarkers associated with a positive clinical response were identified and a prediction model was built to identify sustained responders prior to treatment.

[1]  P. Chow,et al.  Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses , 2017, Proceedings of the National Academy of Sciences.

[2]  Michael B. Stadler,et al.  An Immune Atlas of Clear Cell Renal Cell Carcinoma , 2017, Cell.

[3]  E. Tartour,et al.  Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma. , 2017, Cancer research.

[4]  Andreas Ziegler,et al.  ranger: A Fast Implementation of Random Forests for High Dimensional Data in C++ and R , 2015, 1508.04409.

[5]  H. Friess,et al.  Impact of NKT Cells and LFA-1 on Liver Regeneration under Subseptic Conditions , 2016, PloS one.

[6]  S. Demaria,et al.  Current clinical trials testing the combination of immunotherapy with radiotherapy , 2016, Journal of Immunotherapy for Cancer.

[7]  R. Salem,et al.  Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma , 2016, Advances in Therapy.

[8]  Sungjune Kim,et al.  The immune mechanisms of abscopal effect in radiation therapy. , 2016, Current problems in cancer.

[9]  Ranadip Pal,et al.  S1: Supplementary Information for Article: A copula based S1: Supplementary Information for Article: A copula based approach for design of multivariate random forests for drug approach for design of multivariate random forests for drug sensitivity prediction sensitivity prediction , 2015 .

[10]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[11]  Raymond Ong,et al.  A CD45-based barcoding approach to multiplex mass-cytometry (CyTOF) , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[12]  J. Ertle,et al.  In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[13]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[14]  Andrew D. Luster,et al.  Chemokines in Cancer , 2014, Cancer Immunology Research.

[15]  Leonhard Held,et al.  Spatio-Temporal Analysis of Epidemic Phenomena Using the R Package surveillance , 2014, ArXiv.

[16]  W. Ambrosius,et al.  Application of Random Forests Methods to Diabetic Retinopathy Classification Analyses , 2014, PloS one.

[17]  G. Coukos,et al.  T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. , 2014, Cancer discovery.

[18]  A. Raza,et al.  Hepatocellular carcinoma review: current treatment, and evidence-based medicine. , 2014, World journal of gastroenterology.

[19]  Mark M. Davis,et al.  Automatic Classification of Cellular Expression by Nonlinear Stochastic Embedding (ACCENSE) , 2013, Proceedings of the National Academy of Sciences.

[20]  Sean C. Bendall,et al.  Normalization of mass cytometry data with bead standards , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[21]  N. Copeland,et al.  Toll-Like Receptor 3 Expressing Tumor Parenchyma and Infiltrating Natural Killer Cells in Hepatocellular Carcinoma Patients , 2012, Journal of the National Cancer Institute.

[22]  X. Lu,et al.  Tim‐3/galectin‐9 signaling pathway mediates T‐cell dysfunction and predicts poor prognosis in patients with hepatitis B virus‐associated hepatocellular carcinoma , 2012, Hepatology.

[23]  Bruno Sangro,et al.  Radioembolization for hepatocellular carcinoma. , 2012, Journal of hepatology.

[24]  Steven P Lund,et al.  Statistical Applications in Genetics and Molecular Biology Detecting Differential Expression in RNA-sequence Data Using Quasi-likelihood with Shrunken Dispersion Estimates , 2012 .

[25]  I. Ng,et al.  Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma , 2011, Gut.

[26]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[27]  Lincoln Stein,et al.  Reactome: a database of reactions, pathways and biological processes , 2010, Nucleic Acids Res..

[28]  J. Kirkwood,et al.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.

[29]  Jenna M. Sullivan,et al.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.

[30]  J. George,et al.  Fitness versus fatness: Moving beyond weight loss in nonalcoholic fatty liver disease , 2010, Hepatology.

[31]  M. Loh,et al.  Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. , 2010, Journal of hepatology.

[32]  A. Benson,et al.  Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. , 2010, Gastroenterology.

[33]  B. Gao,et al.  Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases , 2009, Journal of leukocyte biology.

[34]  David E. Anderson,et al.  TIM‐3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines , 2009, European journal of immunology.

[35]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[36]  Max Kuhn,et al.  Building Predictive Models in R Using the caret Package , 2008 .

[37]  N. Kawashima,et al.  Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells1 , 2008, The Journal of Immunology.

[38]  Jin Xu,et al.  Robustified MANOVA with applications in detecting differentially expressed genes from oligonucleotide arrays , 2008, Bioinform..

[39]  S. Gerber,et al.  Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity1 , 2008, The Journal of Immunology.

[40]  W. Swat,et al.  Vav1 Promotes T Cell Cycle Progression by Linking TCR/CD28 Costimulation to FOXO1 and p27kip1 Expression1 , 2006, The Journal of Immunology.

[41]  Mary Helen Barcellos-Hoff,et al.  Radiation and the microenvironment – tumorigenesis and therapy , 2005, Nature Reviews Cancer.

[42]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[43]  G. Clayman,et al.  Chemokines in cancer , 2001, Expert Reviews in Molecular Medicine.

[44]  T. Mak,et al.  Cutting Edge: LFA-1 Is Required for Liver NK1.1+TCRαβ+ Cell Development: Evidence That Liver NK1.1+TCRαβ+ Cells Originate from Multiple Pathways , 1999, The Journal of Immunology.

[45]  T. Mak,et al.  Cutting edge: LFA-1 is required for liver NK1.1+TCR alpha beta+ cell development: evidence that liver NK1.1+TCR alpha beta+ cells originate from multiple pathways. , 1999, Journal of immunology.

[46]  Keith E Muller,et al.  A New F Approximation for the Pillai-Bartlett Trace under H0. , 1998, Journal of computational and graphical statistics : a joint publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America.